Labs / ADME, DMPK & toxicology
Artery Therapeutics
San Ramon, CA, United States · arterytx.com
GLP
Artery Therapeutics is a clinical-stage biotechnology company developing CS6253, an ABCA1 agonist for APOE4-associated Alzheimer’s disease. It is headquartered in San Ramon, California, and is advancing the program through clinical development for APOE4 homozygous carriers with MCI-Alzheimer’s disease.
They take quote requests by email.
What they offer
Drug development for ABCA1-targeted therapies
Develops first-in-class peptide therapies that target ABCA1 to correct lipid transport defects implicated in disease.
Clinical development of CS6253
Advances CS6253 through clinical trials, including Phase 1 completion and Phase 2A planning.
Preclinical pharmacology
Conducts pharmacology studies supporting candidate selection and mechanism-of-action work in disease models.
IND-enabling studies
Performs GLP toxicology and other studies to support Investigational New Drug filing.
CMC development
Carries out chemistry, manufacturing, and controls activities for the program.
Chronic toxicology studies
Runs long-term GLP toxicology studies to support later-stage clinical development.
What they work on
- Modalities
- Small molecule, Peptide
- Species and models
- APOE4 mouse models, primate
- Assays and studies
- GLP toxicology, pharmacology studies, PK studies, amyloid-β mobilization
- Scale and capacity
- 9-month GLP primate study
- Therapeutic areas
- Alzheimer's disease, neurodegenerative diseases, metabolic diseases, cardiovascular diseases
- Sites
- San Ramon, United States
- Quality
- GLP (toxicology)
- Founded
- 2004
Similar labs. Veloxity Labs, Aurigene Pharmaceutical Services, HitGen, MedChem Partners
Found in a contract services directory. Listing built from arterytx.com. Work here? Claim this listing.